Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. Article (PDF Available) in New England Journal of Medicine. The primary outcome was the time to monotherapy failure, which was defined as a Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. FPrime Recommended Article: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
|Published (Last):||24 September 2010|
|PDF File Size:||3.8 Mb|
|ePub File Size:||14.3 Mb|
|Price:||Free* [*Free Regsitration Required]|
The etiology of these defects is not fully understood. The potential risks and benefits, the profile of adverse events, and the costs of these three drugs should all be considered to help inform the choice of pharmacotherapy for patients with type 2 diabetes.
RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus Sarita Bajaj International journal of diabetes in developing….
Disclosures Policy Provide sufficient details of any financial or non-financial competing interests to enable rosiglitazine to assess whether your comments might lead a reasonable person to question your impartiality.
F reserves the right to monitor all Material and to remove any Material which it considers in its absolute glyburidw to be unlawful, inappropriate, offensive or otherwise in breach of these Terms and Conditions. The patients metformon treated for a median of 4. N2 – Background The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known.
This Agreement shall begin on the date hereof.
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. – Semantic Scholar
Nat Clin Pract Endocrinol Metab. Growing evidence from large clinical trials supporting earlier and more aggressive therapeutic strategies to manage hyperglycemia in diabetes has been reflected in current guidelines and practice recommendations 2 — 5. Institutional access Recommend FPrime to your librarian or information manager glybufide request an extended free trial for all users at your institution. New England Journal of MedicineVol. METHODS We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabetes in a double-blind, randomized, controlled clinical trial involving patients.
N Engl J Med. Management of hyperglycemia in glcyemic 2 diabetes: In progress issue alert. A summary of the content will be automatically included. You may not use the website for any unlawful purpose, including without limitation, to upload, post, download or otherwise use any Material that you do not have the copyright owners permission to so upload, post, download or otherwise use, or that would result in you being in breach of these terms and conditions.
Showing of 1, extracted citations. Thus, translation of the ADOPT data supports a role for early use of metformin and rosiglitazone in combination, a well-tolerated, effective initial therapy that has been approved by the U.
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. – FPrime
Please disclose any competing interests that might be construed to influence your judgment of the validity or importance of the article, or any recommendation or review. Citing articles via Web of Science 8. Topics Discussed in This Paper. Email alerts New issue alert. Related articles in Web of Science Google Scholar. Large genomic aberrations in corticotropinomas are associated with greater aggressiveness.
The effect of dietary eurability on distinct components of the metabolic syndrome in a young Sri Lankan population at high risk of CVD Guess, N. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
References Publications referenced by this paper. Recommend FPrime to your librarian or information manager to request an extended free trial for all users at your institution. Piloting a Remission Strategy in Type 2 Diabetes: Prior studies have shown that the combination of these two agents works well and minimizes the side effects of higher doses of each agent without hypoglycemia By clicking “I accept the Terms and Conditions relating to Materials” before you submit your first Material as hereinafter defined you agree to be bound by these conditions every time you submit Material.
By posting Material you grant to F an irrevocable non-exclusive royalty-free license to keep monothsrapy copy of Material for a reasonable period and as necessary to enable it to comply with its legal obligations.
This entry form currently does not support special characters. These data fit with the relatively low frequency of CHF with thiazolidinedione use, including when used in combination with sulfonylureas in elderly patients with a high incidence of baseline edema F does not claim any ownership in the Material that you or any other user posts. Jones and Barbara G.
Sulfonylurea use, especially with aggressive glycemic targets, is not only a poor choice from a durability standpoint, but can be fraught with uncomfortable and potentially dangerous hypoglycemia especially when used in early combinations Prespecified secondary outcomes were levels of fasting plasma glucose and glycated hemoglobin, insulin sensitivity, glyemic beta-cell function.
Rosiglitazne difference in the durability of the treatment effect was greater between rosiglitazone and glyburide than between rosiglitazone and metformin. Examples of ‘Non-Financial Competing Interests’ Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.
Nevertheless, as in clinical practice, we can only surmise that the fraction of patients achieving A1c levels to a goal of 6. Neither of the above. New agents that can further enhance glycemic control perhaps by different mechanisms but also avoiding hypoglycemia, including the incretin agents, will be welcome additions to this therapeutic mix.
The multifactorial nature of T2DM pathogenesis, noted above, is also consistent with a superior clinical response from medication combinations that address several underlying defects at once. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. By posting or uploading Material you warrant and represent that: The duurability outcome was the time to monotherapy failure, which was defined as a confirmed level of fasting plasma glucose of more than mg per deciliter The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known.